Reata Pharma (RETA)

$114.73 1.95 (1.73%)

11:31 EDT RETA Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 2.32B

PE Ratio -75.48

EPS -1.52

Volume (Avg. Vol.) 50,920

Day's Range 112.03 - 116.88

52-Week Range 88.17 - 257.96

Dividend & Yield N/A (N/A)

RETA Stock Predictions, Articles, and Reata Pharma News

From the Web

RETA Selling Below CFO's Recent Buy Price

From Market News Video Sep 3, 2020

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 14, Reata Pharmaceuticals Inc's CFO, Manmeet Singh Soni, invested $300,630.00 into 3,000 shares of RETA, for a cost per share of $100.21..

NASDAQ:RETA Shareholder Notice: Investigation over Potential Wrongdoing at Reata Pharmaceuticals, Inc.

From SBWire Oct 14, 2020

San Diego, CA -- (SBWIRE) -- 10/14/2020 -- Certain directors of Reata Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties.

Reata Pharmaceuticals, Inc. (RETA) Down 6.2% Since Last Earnings Report: Can It Rebound?

From Zacks Investment Research Sep 9, 2020

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Oversold Conditions For Reata Pharmaceuticals (RETA)

From Market News Video Sep 3, 2020

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Top Buys by Top Brass: CFO Soni's $300.6K Bet on RETA

From Market News Video Aug 17, 2020

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

From Zacks Investment Research Aug 11, 2020

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell